University of Southern Denmark Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma

Citation for pulished version (APA): San-Miguel, J., Usmani, S. Z., Mateos, M-V., van de Donk, N. W. C. J., Kaufman, J. L., Moreau, P., Oriol, A., Plesner, T., Benboubker, L., Liu, K., Hellemans, P., Masterson, T., Clemens, P. L., Luo, M., Farnsworth, A., Nahi, H., & Chari, A. (2021). Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica, 106(6), 1725-1732. https://doi.org/10.3324/haematol.2019.243790

[1]  H. Goldschmidt,et al.  Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES) , 2019, Clinical Lymphoma Myeloma and Leukemia.

[2]  T. Plesner,et al.  Subcutaneous Delivery of Daratumumab in Relapsed or Refractory Multiple Myeloma. , 2019, Blood.

[3]  S. Lonial,et al.  High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action , 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[4]  H. Goldschmidt,et al.  Randomized, open-label, phase 3 study of subcutaneous daratumumab (DARA SC) versus active monitoring in patients (Pts) with high-risk smoldering multiple myeloma (SMM): AQUILA. , 2018 .

[5]  M. Dimopoulos,et al.  Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO). , 2018 .

[6]  C. Hofmeister,et al.  Ninety-minute daratumumab infusion is safe in multiple myeloma , 2017, Leukemia.

[7]  T. Plesner,et al.  Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study , 2017 .

[8]  J. Fay,et al.  Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. , 2017, Blood.

[9]  A. Jakubowiak,et al.  Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study. , 2017 .

[10]  S. Lonial,et al.  Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma , 2017, Clinical pharmacology and therapeutics.

[11]  A. Krishnan,et al.  Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma , 2016 .

[12]  H. Goldschmidt,et al.  Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX) , 2016 .

[13]  S. Lonial,et al.  Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment , 2016, Clinical Pharmacokinetics.

[14]  A. Palumbo,et al.  Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2016, Blood.

[15]  H. Goldschmidt,et al.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[16]  A. Palumbo,et al.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[17]  P. Parren,et al.  The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor–Mediated Cross-Linking , 2016, The Journal of Immunology.

[18]  Bie M. P. Verbist,et al.  Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. , 2016, Blood.

[19]  A. Jakubowiak,et al.  Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial , 2016, The Lancet.

[20]  S. Lonial,et al.  Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. , 2015, Blood.

[21]  A. Palumbo,et al.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. , 2015, The New England journal of medicine.

[22]  P. Parren,et al.  Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma , 2015, mAbs.

[23]  P. Parren,et al.  Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79 , 2014 .

[24]  D. Allison,et al.  A Guide to Rational Dosing of Monoclonal Antibodies , 2012, Clinical Pharmacokinetics.

[25]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[26]  Kenneth C. Anderson,et al.  Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors , 2011, The Journal of Immunology.

[27]  Hong Zhao,et al.  Fixed Dosing Versus Body Size—Based Dosing of Monoclonal Antibodies in Adult Clinical Trials , 2009, Journal of clinical pharmacology.

[28]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[29]  C. Scheid,et al.  [Infusion of Daratumumab in Combination Therapies - Practical Information for The Outpatient Area]. , 2018, Deutsche medizinische Wochenschrift.

[30]  Y. Morrison.  presented at the Annual Meeting of the , 1970 .